



RECEIVED

MAY 21 2002

EXPRESS MAIL CERTIFICATE

Date 5/15/02 Label No. EV028648268-US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

TECH CENTER 1600/2900  
PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

D BREW [Signature]  
Name (Print) Signature

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No: 1034/1F808US7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Peter H. St. George-Hyslop, et al.

Serial No.: 09/689,159

Art Unit: 1647

Confirmation No.: 2656

Filed: October 12, 2000

Examiner: Robert S. Landsman

For: **GENETIC SEQUENCES AND PROTEINS RELATED TO ALZHEIMER'S DISEASE**

MARK-UP FOR RESPONSE TO RESTRICTION REQUIREMENT  
AND PRELIMINARY AMENDMENT

Hon. Commissioner of  
Patents and Trademarks  
Washington, DC 20231

May 14, 2002

IN THE SPECIFICATION:

In the substitute specification, please amend the paragraph on page 1,  
lines 5-8, to read as follows:

This application is a divisional of U.S. Patent Application Serial No. 08/509,359, filed July 31, 1995, which is a continuation-in-part of U.S. Patent Application Serial No. 08/496,841, filed June 28, 1995, which is a continuation-in-part of U.S. Patent Application Serial No. 08/431,048, filed April 28, 1995.

In the substitute specification, please amend the paragraph on page 91, lines 30-31, to read as follows:

Polyclonal antibody 1: NDNRERQEHNDRRSL (C) - residues 30-[45]44

In the substitute specification, please amend the paragraph on page 92, lines 1-2, to read as follows:

Polyclonal antibody 2: KDGQLIYTPFTEDTE (C) - residues 109-[120]123

In the substitute specification, please amend the paragraph on page 91, lines 3-4, to read as follows:

Polyclonal antibody 3: EAQRRVSKNSKYNAE (C) - residues 304-[319]318

**IN THE CLAIMS:**

Please amend the claims according to 37 C.F.R. 1.121 as follows:

74. (Amended) The antibody as defined in claim 73, wherein the mammalian Presenilin protein has a sequence as depicted in SEQ ID NOs:2, 4, 134, 136, or [137] 138.

75. (Amended) The antibody as defined in claim 73, which selectively recognizes an amino acid sequence of at least six contiguous amino acid residues as depicted in SEQ ID NOs:2, 4, 134, 136, or [137] or 138; or antigenic fragments.

76. (Amended) The antibody as defined in claim 75, wherein the antibody selectively recognizes amino acid residues 30-[45]44, 109-[120]123, 304-[319]318, or 346-360 of SEQ ID NO:2.

81. (Amended) The method as defined in claim 80, wherein the mammalian Presenilin protein has a sequence as depicted in SEQ ID NOs: 2, 4, 134, 136, or [137] 138.